Indoco Remedies announced that it has received EU GMP accreditation from Malta’s Competent Health Authority for its Baddi (Unit -I) manufacturing location in Village Katha, Tehsil- Nalagarh, District- Solan, Himachal Pradesh.
From April 20 to 24, 2023, the Agency inspected Indoco’s manufacturing facility for solid oral dosage form.
Aditi Panandikar, Managing Director of Indoco Remedies Ltd., commented on the development, saying, “The EU GMP certification for our site in Baddi (Unit I) further bolsters our capability as a company to supply quality and affordable medicines in Europe and other geographies. We are devoted to remaining cGMP compliant and providing excellent products to our customers and patients worldwide.”
The EU GMP accreditation provided by Malta’s Health Authority shows that the location complies with the EC Directive’s Good Manufacturing Practice criteria. The EU GMP certification will help this manufacturing location supply drugs to Europe and other countries.
At around 1.50 PM, Indoco Remedies was trading 1.83% lower at Rs 316.95, against the previous close of Rs 322.85 on NSE. The counter touched an intraday high and low of Rs 332.10 and Rs 316.35, respectively.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.